{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:42Z","timestamp":1794018582526,"version":"4.8.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Outcomes are poor in triple-class\u2013exposed (TCE) relapsed and refractory multiple myeloma (R\/RMM). In the phase 3 KarMMa-3 trial, patients with TCE R\/RMM and 2 to 4 prior regimens were randomized 2:1 to idecabtagene vicleucel (ide-cel) or standard regimens (SRs). An interim analysis (IA) demonstrated significantly longer median progression-free survival (PFS; primary end point; 13.3 vs 4.4 months; P\u00a0&amp;lt; .0001) and higher overall response rate (ORR) with ide-cel vs SRs. At final PFS analysis (median follow-up, 30.9 months), ide-cel further improved median PFS vs SRs (13.8 vs 4.4 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.38-0.63). PFS benefit with ide-cel vs SRs was observed regardless of number of prior lines of therapy, with greatest benefit after 2 prior lines (16.2 vs 4.8 months, respectively). ORR benefit was maintained with ide-cel vs SRs (71% vs 42%; complete response, 44% vs 5%). Patient-centric design allowed crossover from SRs (56%) to ide-cel upon progressive disease, confounding overall survival (OS) interpretation. At IA of OS, median was 41.4 (95% CI, 30.9 to not reached [NR]) vs 37.9 (95% CI, 23.4 to NR) months with ide-cel and SRs, respectively (HR, 1.01; 95% CI, 0.73-1.40); median OS in both arms was longer than historical data (9-22 months). Two prespecified analyses adjusting for crossover showed OS favoring ide-cel. This trial highlighted the importance of individualized bridging therapy to ensure adequate disease control during ide-cel manufacturing. Ide-cel improved patient-reported outcomes vs SRs. No new safety signals were reported. These results demonstrate the continued favorable benefit-risk profile of ide-cel in early-line and TCE R\/RMM. This trial was registered at www.ClinicalTrials.gov as #NCT03651128.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024024582","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T15:16:03Z","timestamp":1724858163000},"page":"2389-2401","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":86,"title":["Ide-cel vs standard regimens in triple-class\u2013exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses"],"prefix":"10.1182","volume":"144","author":[{"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[{"name":"2Immuno-H\u00e9matologie, H\u00f4pital Saint-Louis, l'Assistance publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris Cite, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina","family":"Patel","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma-Myeloma, MD Anderson Cancer Center, The University of Texas, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"4Department of Medical and Surgical Sciences, Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Ser\u00e0gnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"6Medical and Oncology Specialties Department, Centre Hospitalier Universitaire de Lille, Universit\u00e9 de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1086","authenticated-orcid":false,"given":"Natalie","family":"Callander","sequence":"additional","affiliation":[{"name":"7Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"8Hematology & Oncology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[{"name":"9Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"10Department of Oncology, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"11Hematology Department, University Hospital of Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Solomon","sequence":"additional","affiliation":[{"name":"12Transplant and Cellular Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6875-1159","authenticated-orcid":false,"given":"Ingerid Weum","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"13Department of Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"14Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chen","sequence":"additional","affiliation":[{"name":"16Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"17Multiple Myeloma Center of Excellence at Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"18Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[{"name":"19Department of Medicine, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Benjamin","sequence":"additional","affiliation":[{"name":"21Department of Heamatology, Kings College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"22Department of Medical Oncology, Bern University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-960X","authenticated-orcid":false,"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"23Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jes\u00fas","family":"Berdeja","sequence":"additional","affiliation":[{"name":"24Sarah Cannon Cancer Center and Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"25Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Truppel-Hartmann","sequence":"additional","affiliation":[{"name":"262seventy bio, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Chen","sequence":"additional","affiliation":[{"name":"27Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhong","sequence":"additional","affiliation":[{"name":"27Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[{"name":"27Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Piasecki","sequence":"additional","affiliation":[{"name":"27Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Eliason","sequence":"additional","affiliation":[{"name":"27Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devender","family":"Dhanda","sequence":"additional","affiliation":[{"name":"27Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Felten","sequence":"additional","affiliation":[{"name":"28Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Caia","sequence":"additional","affiliation":[{"name":"28Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cook","sequence":"additional","affiliation":[{"name":"28Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Popa McKiver","sequence":"additional","affiliation":[{"name":"27Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[{"name":"29Department of Hematology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2024120516204720100_bib1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.17888","article-title":"Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period","volume":"196","author":"Rodriguez-Lobato","year":"2022","journal-title":"Br J Haematol"},{"issue":"11","key":"2024120516204720100_bib2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2024120516204720100_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"2024120516204720100_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","article-title":"Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma","volume":"22","author":"Dimopoulos","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024120516204720100_bib5","author":"Chari","year":"25-27  2021"},{"issue":"9","key":"2024120516204720100_bib6","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2024120516204720100_bib7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2024120516204720100_bib8","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/S2152-2650(22)00595-X","article-title":"Treatment patterns and outcomes of patients with triple-class exposed relapsed or refractory multiple myeloma: analysis of the Optum electronic health records and commercial claims database","volume":"22","author":"Kumar","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2024120516204720100_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clml.2022.11.008","article-title":"Treatment patterns, survival, quality of life, and healthcare resource use among patients with triple-class refractory multiple myeloma in US clinical practice: findings from the Connect MM Disease Registry","volume":"23","author":"Lee","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl2","key":"2024120516204720100_bib10","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/S2152-2650(23)01903-1","article-title":"P-285Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connect multiple myeloma disease registry","volume":"23","author":"Lee","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"S3","key":"2024120516204720100_bib11","doi-asserted-by":"crossref","first-page":"e642555a","DOI":"10.1097\/01.HS9.0000970684.64255.5a","article-title":"Real-world clinical outcomes among triple-class exposed relapsed refractory multiple myeloma patients in US and Europe: a PREAMBLE registry study","volume":"7","author":"Ramasamy","year":"2023","journal-title":"HemaSphere"},{"issue":"suppl1","key":"2024120516204720100_bib12","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1016\/S2152-2650(23)01455-6","article-title":"MM-464 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed\/refractory multiple myeloma\u2013final analysis at 2-year follow-up","volume":"23","author":"Moreau","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2024120516204720100_bib13","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024120516204720100_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2024120516204720100_bib15","first-page":"3473","article-title":"CAR T-cell therapy: is it prime time in myeloma?","volume":"3","author":"Sidana","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2024120516204720100_bib16","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 suppl","key":"2024120516204720100_bib17","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2021.39.15_suppl.8013","article-title":"CARTITUDE-2: efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy","volume":"39","author":"Agha","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024120516204720100_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2024120516204720100_bib19","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024120516204720100_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"issue":"16 suppl","key":"2024120516204720100_bib21","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1200\/JCO.2022.40.16_suppl.8029","article-title":"Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B","volume":"40","author":"van de Donk","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"2024120516204720100_bib22","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1016\/S2152-2650(23)01449-0","article-title":"Idecabtagene vicleucel (ide-cel) versus standard regimens in patients With triple-class\u2013exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in high-risk subgroups","volume":"23","author":"Patel","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2024120516204720100_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/105294199277860","article-title":"The International Conference on Harmonization Good Clinical Practice guideline","volume":"6","author":"Dixon","year":"1998","journal-title":"Qual Assur"},{"issue":"8","key":"2024120516204720100_bib24","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024120516204720100_bib25","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) v4. 03","year":"2010"},{"issue":"2","key":"2024120516204720100_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2024120516204720100_bib27","volume-title":"Question and Answer on Adjustment for Cross-Over in Estimating Effects in Oncology Trials","year":"2018"},{"issue":"3","key":"2024120516204720100_bib28","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","article-title":"Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"2024120516204720100_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"23","key":"2024120516204720100_bib30","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"2024120516204720100_bib31","doi-asserted-by":"crossref","first-page":"100757","DOI":"10.1016\/j.blre.2020.100757","article-title":"Second primary malignancies in multiple myeloma: a review","volume":"46","author":"Poh","year":"2021","journal-title":"Blood Rev"},{"key":"2024120516204720100_bib32","unstructured":"National Cancer Institute\n          . SEER\u2217Explorer. Myeloma. Accessed 11 July 2024. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024024582\/2319039\/blood_bld-2024-024582-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024024582\/2319039\/blood_bld-2024-024582-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T11:21:03Z","timestamp":1733397663000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/23\/2389\/517598\/Ide-cel-vs-standard-regimens-in-triple-class"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":32,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024582","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}